Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 20

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 20
---
                         
 of preparing an application for clinical trials and FDA approvals of our product candidates’ development programs. |

| ● | FDA approval in general |

| ● | Higher than expected costs                                                                                                        
 to further develop and scale up manufacturing of our therapeutic candidates through CDMOs (Contract Development and Manufacturing 
 Organizations).                                                                                                                   |

| ● | Competition for our products |

| ● | Our ability to achieve                                                                                                                 
 milestones under licensing arrangements and the costs involved in enforcing or defending patent claims and other intellectual property 
 rights.                                                                                                                                |

To date, we have financed our operations through
a mix of equity investments from private investors, and we expect to continue to utilize such means of financing for the foreseeable
future. However, additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms,
or at all.

If we raise capital through the sale of equity,
or securities convertible into equity, it will result in dilution to our then existing stockholders, which could be significant depending
on the price at which we may be able to sell our securities.

If we raise additional capital through the incurrence
of indebtedness, we may become subject to covenants restricting our business activities, and holders of debt instruments may have rights
and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under
debt facilities could divert funds that would otherwise be available to support research and development or commercialization activities.
Any debt financing that we obtain in the future could involve substantial restrictions on activities and creditors could seek a pledge
of some or all of our assets. We have not identified potential sources for such financing that we will require, and we do not have commitments
from any third parties to provide any future debt financing.

If we are unable to raise capital when needed
on commercially reasonable terms, we could be forced to delay, reduce or eliminate our research and development for our product candidates
or any future commercialization efforts or ultimately cease operations. Any of these events could significantly harm our business, financial
condition and prospects.

We anticipate that we can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to comply with LipoVation’s contractual obligations under the Yissum License Agreements or other licenses or related agreements to which we may be a party in the future, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles (NLP)-based medicines based therapeutic products.